Latest News
-
DUBLIN, Ireland, and Boston MA, December 23, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce today that the U.S. Food and Drug Administration (“FDA”) has granted orphan... -
ST. LOUIS, Dec. 15, 2020 /PRNewswire/ — Centene Corporation (NYSE: CNC) today announced it has signed a definitive agreement to acquire PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and rare diseases. The transaction is subject to regulatory approvals and is expected to close by the end of...
-
At the start of the year, pharmacy benefit manager OptumRx predicted that 40% of all new FDA-approved products in 2020 would be orphan drugs. The PBM hasn’t changed that forecast, but it has come out with a bold new prediction about drugs that address small patient populations. Developers of orphan...
Videos
Rare disease spotlight
In today's #DecodingDravet blog @Science_Hood discusses what to consider before sharing too many personal details on #socialmedia while in an active #clinicaltrial https://www.dravetfoundation.org/why-be-cautious-about-sharing-personal-experiences-in-an-active-clinical-trial-2021-01-22/
